Cyteir to dis­solve as on­col­o­gy biotech scraps its fi­nal clin­i­cal at­tempt two years af­ter IPO

Cyteir Ther­a­peu­tics will dis­solve, liq­ui­date and re­turn re­main­ing cash to share­hold­ers, the Lex­ing­ton, MA-based biotech said Fri­day morn­ing.

The pub­lic com­pa­ny said its in­ves­ti­ga­tion­al drug didn’t clear the ef­fi­ca­cy hur­dles need­ed to move be­yond a Phase I com­bi­na­tion study. Cyteir tried pair­ing CYT-0851 with the chemother­a­py capecitabine and gem­c­itabine, which is usu­al­ly com­bined with oth­er on­col­o­gy drugs. The ear­ly-stage study in­clud­ed pa­tients with ad­vanced ovar­i­an can­cer and oth­er sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER